Biosimilar is a biologic medical product which is highly similar to another already approved biological medicine.
This report contains market size and forecasts of Adalimumab, Infliximab And Etanercept Biosimilars in global, including the following market information:
Global Adalimumab, Infliximab And Etanercept Biosimilars Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Adalimumab, Infliximab And Etanercept Biosimilars Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Adalimumab, Infliximab And Etanercept Biosimilars companies in 2021 (%)
The global Adalimumab, Infliximab And Etanercept Biosimilars market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Adalimumab Biosimilars Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Adalimumab, Infliximab And Etanercept Biosimilars include Boehringer Ingelheim, Abbvie, Cipla Ltd, Hetero Drugs Limited, Pfizer, Novartis, Samsung Bioepis(Samsung Biologics), Amgen and Celltrion Healthcare, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Adalimumab, Infliximab And Etanercept Biosimilars manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Adalimumab, Infliximab And Etanercept Biosimilars Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Adalimumab, Infliximab And Etanercept Biosimilars Market Segment Percentages, by Type, 2021 (%)
Adalimumab Biosimilars
Infliximab Biosimilars
Etanercept Biosimilars
Global Adalimumab, Infliximab And Etanercept Biosimilars Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Adalimumab, Infliximab And Etanercept Biosimilars Market Segment Percentages, by Application, 2021 (%)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Adalimumab, Infliximab And Etanercept Biosimilars Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Adalimumab, Infliximab And Etanercept Biosimilars Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Adalimumab, Infliximab And Etanercept Biosimilars revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Adalimumab, Infliximab And Etanercept Biosimilars revenues share in global market, 2021 (%)
Key companies Adalimumab, Infliximab And Etanercept Biosimilars sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Adalimumab, Infliximab And Etanercept Biosimilars sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Boehringer Ingelheim
Abbvie
Cipla Ltd
Hetero Drugs Limited
Pfizer
Novartis
Samsung Bioepis(Samsung Biologics)
Amgen
Celltrion Healthcare
Mylan
HETERO
Glenmark Pharmaceuticals
Emcure Pharmaceuticals